The New England journal of medicine

• Latest
• Best
• Search…

• N. Engl. J. Med. · Nov 2018

  Review

  Lymphedema after Breast Cancer Treatment.

  no abstract available

  expand abstract… or not…

• N. Engl. J. Med. · Nov 2018

  Comment Letter

  Procalcitonin-Guided Antibiotic Use.

  no abstract available

  expand abstract… mark as read…

• N. Engl. J. Med. · Nov 2018

  Randomized Controlled Trial Multicenter Study

  Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.

  The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib, in combination with fulvestrant therapy, prolongs progression-free survival among patients with hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. We report the results of a prespecified analysis of overall survival. ⋯ Among patients with hormone-receptor-positive, HER2-negative advanced breast cancer who had sensitivity to previous endocrine therapy, treatment with palbociclib-fulvestrant resulted in longer overall survival than treatment with placebo-fulvestrant. The differences in overall survival in the entire trial group were not significant. (Funded by Pfizer; PALOMA-3 ClinicalTrials.gov number, NCT01942135 .).

  read more… mark as read…

• N. Engl. J. Med. · Nov 2018

  Reimagining Development Assistance for Health.

  no abstract available

  read on… or not…

• N. Engl. J. Med. · Nov 2018

  Comment Letter

  Ibrutinib and Rituximab in Waldenström's Macroglobulinemia.

  no abstract available

  expand abstract… or just mark as read…